High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
about
High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancerDose-dense adjuvant chemotherapy for primary breast cancer.High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancerHaptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach.Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation.Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyLack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastasesPostoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis.The epidermal growth factor receptor family in breast cancer.Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients.Why now is the time to enact health care reformAn aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.Haematopoietic stem cell transplantation: indications, clinical developments and future directions.Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.Companion diagnostics: changing patient managementCardiac toxicity of high-dose chemotherapy.Dose density in adjuvant chemotherapy for breast cancer.High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer.Transplantation of hematopoietic stem cells from the peripheral blood.Controversies in breast cancer: adjuvant and neoadjuvant therapy.Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapyCardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective studyHigh exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapyThe analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancerDoes autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.Radio-photothermal therapy mediated by a single compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in the orthotopic 4T1 breast tumor model.Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapyThe effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic reviewInnovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.High-dose chemotherapy of cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation as a consolidation for breast cancer patients with 10 or more positive lymph nodes: a 5-year follow-up results.
P2860
Q24246510-5C2CEA06-62B7-4AF7-AAE7-0DDB48A78C8AQ24797259-1754BC36-8E42-423F-9285-7DF12032DE08Q26471974-F430486F-0B03-48C3-A433-E3D906D876DBQ33395871-3CEC7C4E-E037-4114-904E-4FAC3F33CB99Q33583564-3F08AE63-FD4D-4B02-B7C7-BFB585E46708Q33702336-C1F9B174-538E-45BF-9D39-18469EAABE48Q33827045-269B453A-381F-434F-9C7E-54D2AA0D1F63Q33988970-3A06D0AD-C8B2-4CD5-8CEB-BBF1B4A315C7Q34018095-7BC408A0-1A47-4BE0-95BC-5821E52C50F9Q34200900-F0992F8E-FCF8-4228-8CC4-68B2E4E8026DQ34363400-103CCA39-3170-480C-A11E-18592D89EAC1Q34587999-FC846150-6495-4212-9375-946373ACB56EQ34675363-368C528E-0AE0-4379-AF2C-20FAB0277A86Q35064705-949CBB88-9F1B-4F14-85DD-0E4EFA0880ADQ35065084-7FD931DB-9735-4108-88BF-184E89BED1A4Q35238008-2B7582DA-F300-4A9B-B0A1-C5016E537F6FQ35583968-20C652E9-76B4-45C0-8D0A-15478C52514FQ35609690-B85D46C2-1B1F-486F-9165-BB9DB59390B7Q35683623-17F1DC56-F27A-4DCA-A544-9A0C11D5A931Q35818050-894BBFE3-E3D0-423D-A766-9FB27D2AA322Q35949084-5B4C4A54-1FC4-4FA3-A3A5-BEC43B2CF366Q35964407-29DA6BE1-8F0F-4DBD-A3B7-31760E754D3CQ36028731-47079BC7-8D67-40F3-A137-8AAE37C390FEQ36077380-5200D97E-27B8-4A65-AEEC-7293E4E39489Q36163952-A2C6D22F-D00D-4512-A47A-7CCB91340AF9Q36456104-1ED16044-A907-46FA-95F2-61D16679B3E5Q36611996-2A23BFEC-AFB4-4A94-9A0E-E1F55FAD7541Q36613992-F801CA58-D31E-44DA-AD93-C3067E0181F8Q36614634-14958E52-DE0B-4DEB-B29B-9627377DB899Q36615818-DA6C8729-7E7D-4BED-82B4-6738348FA3C1Q36672691-7B6D3E6E-FE0F-4CB6-8A72-00A3D0820F81Q36879127-C3868BD7-F8B0-492D-8F80-80FB0587F09DQ37049920-37331E26-83A4-471B-A910-9CD07AF3F5C3Q37156272-EA64B516-1B27-44EB-A897-18608107FD5BQ37193545-7D8ED328-637B-4F2B-B9D3-E463E7A29967Q37259756-A68F48CF-AF3E-42E6-9F9E-1E157AEDE98BQ37289219-CD1A1295-E79E-460C-8CA9-E25D5F191A25Q37309845-C0DBD7FE-8B21-48EF-8EA3-F12720046E26Q37404683-3787198C-6168-46DC-BB03-7D1604CC6F44Q37447014-32F0D193-9534-4D07-B385-6C803788AC71
P2860
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
@en
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
@nl
type
label
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
@en
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
@nl
prefLabel
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
@en
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
@nl
P2093
P356
P1476
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer
@en
P2093
Dick J Richel
Elisabeth M TenVergert
Emile E Voest
Hans L Peterse
Harm van Tinteren
Louk V A M Beex
Marianne A Nooij
Marijke Bontenbal
Netherlands Working Party on Autologous Transplantation in Solid Tumors
Pierre Hupperets
P356
10.1056/NEJMOA022794
P407
P577
2003-07-01T00:00:00Z